2025 (4 POSTS)
Nordyke RJ , Patterson JA, Motyka J, March B, Kirson NY, Long G. 2025. The impact of the Inflation Reduction Act’s drug price negotiation program on incentives for clinical development of new drugs. Value Health; doi: 10.1016/j.jval.2025.08.011 . Online ahead of print Sept. 1, 2025. PMID: 40902797.
View Abstract
Topics: drug development
Nordyke RJ , Motyka J, Patterson JA. 2025. The association of 340B program drug margins with covered entity characteristics. Inquiry 62(Jan-Dec):469580251324051; doi: 10.1177/00469580251234051 . PMID: 4012322.
View Abstract
Topics: Health Economics and Outcomes Research (HEOR)
Shafrin J, Wang S, Sharma K, Spurrier K, Nordyke RJ . 2025. Will the Institute for Clinical and Economic Review’s shared savings approach decrease value-based prices most for the most severe diseases? Value Health 28(1):25-30; doi: 10.1016/j.val.2024.09.002 . PMID: 39357669.
View Abstract
Topics: Health Economics and Outcomes Research (HEOR)
Patterson JA, Motyka J, Salih R, Nordyke RJ , O’Brien JM, Campbell JD. 2025. Subsequent indications in oncology drugs: Pathways, timelines, and the Inflation Reduction Act. Ther Innov Regul Sci 59(1):102-111; doi: 10.1007/s43441-024-00706-6 . PMID: 39369117.
View Abstract
Topics: drug development
2024 (1 POST)
Davison NJ, Guthrie NL, Medland S, Lupinacci P, Nordyke RJ , Berman MA. 2024. Cost-effectiveness analysis of a prescription digital therapeutic in Type 2 diabetes. Adv Ther 41(2):806-825; doi: 10.1007/s12325-023-02752-2 . PMID: 38170435.
View Abstract
Topics: diabetes , Health Economics and Outcomes Research (HEOR)
2020 (1 POST)
Su J, Bylsma LC , Jiang X , Morales Arias J, Jain N, Nordyke RJ . 2020. Healthcare resource utilization among commercially insured patients with cold agglutinin disease in the United States. J Med Econ 23(8):902-907; doi: 10.1080/13696998.2020.1764006 .
View Abstract
Topics: Health Economics and Outcomes Research (HEOR)
2019 (4 POSTS)
Nordyke RJ , Reichert H , Bylsma LC , Jackson JJ, Gage SM, Fryzek J, Roy-Chaudhury P, Lithgow T. 2019. Costs attributable to arteriovenous fistula and arteriovenous graft placements in hemodialysis patients with Medicare coverage. Am J Nephrol 50(4):320-328; doi: 10.1159/000502507 . PMID: 31434095.
View Abstract
Topics: Health Economics and Outcomes Research (HEOR)
Su J, Bylsma LC, Jiang X , Morales Arias J, Jain N, Nordyke RJ . Healthcare resource utilization among commercially insured cold agglutinin disease patients in the United States. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research, New Orleans, LA, May 2019.
Topics: Health Economics and Outcomes Research (HEOR)
Fryzek J, Bylsma LC, Nordyke RJ , Sorensen HT. Rare disease epidemiology: A Danish population-based program. Poster presented at the International Society for Pharmacoepidemiology, Philadelphia, PA, August 2019.
Topics: Epidemiology
Bylsma LC , Reichert H , Gage SM, Roy-Chaudhury P, Nordyke RJ , Fryzek J, Dahl SLM, Lithgow T, Lawson JH. 2019. Clinical outcomes of arteriovenous access in incident hemodialysis patients with Medicare coverage, 2012–2014. Am J Nephrol 49(2):156–164, doi: 10.1159/000495355 .
View Abstract